Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alto Neuroscience, Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness of its drug ALTO-100 for treating major depressive disorder (MDD) [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the September 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Alto [4]. - Investors who purchased Alto stock during the class period from February 2, 2024, to October 22, 2024, are encouraged to discuss their legal rights [1][4]. - The complaint alleges that Alto and its executives made false statements regarding ALTO-100's effectiveness, overstating its clinical and commercial prospects [6]. Group 2: Stock Performance and Market Reaction - Following the announcement on October 22, 2024, that ALTO-100 did not meet its primary endpoint in a Phase 2b trial, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share [7]. - Analysts reacted swiftly, with Jeffries reducing its price target for Alto from $33 to $17, citing concerns about the company's biomarker approach to CNS disorders [8]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [5].